New bladder cancer combo shows promise for Tough-to-Treat cases
NCT ID NCT03022825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for people with a type of bladder cancer that has not improved with standard therapy. The treatment combines a standard immunotherapy (BCG) with an experimental drug (N-803), both given directly into the bladder through a catheter. The goal is to see if this combination can control the cancer and prevent it from coming back. About 190 adults with high-grade non-muscle invasive bladder cancer are participating.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCG-UNRESPONSIVE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accument Rx
Albuquerque, New Mexico, 87109, United States
-
Adult & Pediatric Urology
Omaha, Nebraska, 68114, United States
-
Alaska Clinical Research Center
Anchorage, Alaska, 99503, United States
-
Arkansas Urology
Little Rock, Arkansas, 72211, United States
-
Associated Urologists of North Carolina
Raleigh, North Carolina, 27612, United States
-
Clinical Research Center of Florida
Pompano Beach, Florida, 33060, United States
-
Dwight D. Eisenhower Army Medical Center
Augusta, Georgia, 30905, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
Integrated Medical Professionals
New York, New York, 10016, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Madigan Army Medical Center
Tacoma, Washington, 98431, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, 12601, United States
-
Roswell Park Cancer Insitute
Buffalo, New York, 14263, United States
-
Skyline Urology
Sherman Oaks, California, 91411, United States
-
Skyline Urology
Torrance, California, 90505, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UCLA Department of Urology
Los Angeles, California, 90024, United States
-
UNC Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Hawaii Cancer Center
Honolulu, Hawaii, 96814, United States
-
University of Miami Miller School of Medicine-Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Urology Associates, PC
Englewood, Colorado, 80113, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Virginia Urology
Richmond, Virginia, 23235, United States
-
Winthrop University Hospital Department of Urology
Garden City, New York, 11530, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can removing bladder tumors in one piece improve cancer outcomes?
- Can an AI agent match expert urologists? a major test begins
- Can a hybrid surgical technique better remove large bladder tumors?
- Can an AI camera on a catheter spot bladder cancer better than standard scopes?
- Bladder cancer breakthrough? new combo aims to save the bladder
- New combination aims to save bladders in Muscle-Invasive cancer